{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:51:49Z","timestamp":1787845909879,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.7759\/cureus.100822","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:51:35Z","timestamp":1767617495000},"source":"Crossref","is-referenced-by-count":2,"title":["Cardiotoxicity of Chemoradiotherapy in Patients With Esophageal Cancer: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Cyril","family":"Kocherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Jhakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moath","family":"Al-Shudifat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Sumra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Kashmer","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100969","article-title":"Cardiac substructures dosimetric predicts cardiac toxicity and prognosis in esophageal squamous cell cancer treated by radiotherapy","volume":"48","author":"Jin Z","year":"2024","unstructured":"Jin Z, Sun X, Zhou C, Yang H, Zhou S. Cardiac substructures dosimetric predicts cardiac toxicity and prognosis in esophageal squamous cell cancer treated by radiotherapy. Neoplasia. 2024, 48:100969. 10.1016\/j.neo.2024.100969","journal-title":"Neoplasia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2020.02.005","article-title":"Cardiotoxicity of radiation therapy in esophageal cancer","volume":"25","author":"Vo\u0161mik M","year":"2020","unstructured":"Vo\u0161mik M, Hodek M, Buka D, et al.. Cardiotoxicity of radiation therapy in esophageal cancer. Rep Pract Oncol Radiother. 2020, 25:318-22. 10.1016\/j.rpor.2020.02.005","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10260-8","article-title":"MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis","volume":"34","author":"Folco G","year":"2024","unstructured":"Folco G, Monti CB, Zanardo M, Silletta F, Capra D, Secchi F, Sardanelli F. MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis. Eur Radiol. 2024, 34:2699-710. 10.1007\/s00330-023-10260-8","journal-title":"Eur Radiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2020.11.027","article-title":"15-year experience with multimodality therapy including esophagectomy for elderly patients with locoregional esophageal cancer","volume":"232","author":"Sawyer WP","year":"2021","unstructured":"Sawyer WP, Luo X, Welch AM, Bolton NM, Brown R, Bolton JS. 15-year experience with multimodality therapy including esophagectomy for elderly patients with locoregional esophageal cancer. J Am Coll Surg. 2021, 232:580-8. 10.1016\/j.jamcollsurg.2020.11.027","journal-title":"J Am Coll Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.09.015","article-title":"NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer","volume":"141","author":"Thomas M","year":"2019","unstructured":"Thomas M, Defraene G, Lambrecht M, et al.. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol. 2019, 141:33-40. 10.1016\/j.radonc.2019.09.015","journal-title":"Radiother Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.885699","article-title":"Treatment-related coronary disorders of fluoropyrimidine administration: a systematic review and meta-analysis","volume":"13","author":"Lu Y","year":"2022","unstructured":"Lu Y, Deng S, Dou Q, et al.. Treatment-related coronary disorders of fluoropyrimidine administration: a systematic review and meta-analysis. Front Pharmacol. 2022, 13:885699. 10.3389\/fphar.2022.885699","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano G","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al.. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020, 31:171-90. 10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets","volume":"26","author":"Fabiani I","year":"2021","unstructured":"Fabiani I, Aimo A, Grigoratos C, et al.. Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Fail Rev. 2021, 26:881-90. 10.1007\/s10741-020-10063-9","journal-title":"Heart Fail Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.014","article-title":"Incidence and onset of severe cardiac events after radiotherapy for esophageal cancer","volume":"15","author":"Wang X","year":"2020","unstructured":"Wang X, Palaskas NL, Yusuf SW, et al.. Incidence and onset of severe cardiac events after radiotherapy for esophageal cancer. J Thorac Oncol. 2020, 15:1682-90. 10.1016\/j.jtho.2020.06.014","journal-title":"J Thorac Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.03.21","article-title":"Mortality from heart disease following radiotherapy in esophageal carcinoma: a retrospective cohort study in US SEER cancer registry","volume":"9","author":"Zhai H","year":"2020","unstructured":"Zhai H, Huang Y, Li L, Zhang X, Yao J. Mortality from heart disease following radiotherapy in esophageal carcinoma: a retrospective cohort study in US SEER cancer registry. Transl Cancer Res. 2020, 9:2556-64. 10.21037\/tcr.2020.03.21","journal-title":"Transl Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.01.004","article-title":"A multi-institutional analysis of radiation dosimetric predictors of toxicity after trimodality therapy for esophageal cancer","volume":"11","author":"Garant A","year":"2021","unstructured":"Garant A, Spears G, Routman D, et al.. A multi-institutional analysis of radiation dosimetric predictors of toxicity after trimodality therapy for esophageal cancer. Pract Radiat Oncol. 2021, 11:e415-25. 10.1016\/j.prro.2021.01.004","journal-title":"Pract Radiat Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.05.036","article-title":"Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy","volume":"149","author":"Lan K","year":"2020","unstructured":"Lan K, Zhu J, Zhang J, et al.. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2020, 149:228-35. 10.1016\/j.radonc.2020.05.036","journal-title":"Radiother Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01570-y","article-title":"Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer","volume":"15","author":"Celik E","year":"2020","unstructured":"Celik E, Baus W, Baues C, et al.. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol. 2020, 15:120. 10.1186\/s13014-020-01570-y","journal-title":"Radiat Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rraa001","article-title":"Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram","volume":"61","author":"Takeuchi Y","year":"2020","unstructured":"Takeuchi Y, Murakami Y, Kameoka T, et al.. Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram. J Radiat Res. 2020, 61:298-306. 10.1093\/jrr\/rraa001","journal-title":"J Radiat Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-184","article-title":"Doses of intensity-modulated radiotherapy and its association with cardiac disease in esophageal cancer patients","volume":"9","author":"Zhang J","year":"2021","unstructured":"Zhang J, Lv Y, Chen F, Wang X, Zhang L, Zhang X. Doses of intensity-modulated radiotherapy and its association with cardiac disease in esophageal cancer patients. Ann Transl Med. 2021, 9:166. 10.21037\/atm-21-184","journal-title":"Ann Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14026","article-title":"Investigation of the efficacy of the change ratio of brain natriuretic peptide for predicting the cardiac effects of chemoradiotherapy on esophageal cancer","volume":"26","author":"Hatayama Y","year":"2023","unstructured":"Hatayama Y, Kudo S, Ota R, et al.. Investigation of the efficacy of the change ratio of brain natriuretic peptide for predicting the cardiac effects of chemoradiotherapy on esophageal cancer. Oncol Lett. 2023, 26:439. 10.3892\/ol.2023.14026","journal-title":"Oncol Lett"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02290-5","article-title":"Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system","volume":"28","author":"Miyoshi S","year":"2023","unstructured":"Miyoshi S, Nishibuchi I, Murakami Y, et al.. Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system. Int J Clin Oncol. 2023, 28:382-91. 10.1007\/s10147-023-02290-5","journal-title":"Int J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.11.029","article-title":"Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study","volume":"167","author":"Beukema JC","year":"2022","unstructured":"Beukema JC, de Groot C, Plukker JT, et al.. Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study. Radiother Oncol. 2022, 167:72-7. 10.1016\/j.radonc.2021.11.029","journal-title":"Radiother Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-023-00587-0","article-title":"Cardiotoxicity of anti-cancer radiation therapy: a focus on heart failure","volume":"20","author":"Ritter A","year":"2023","unstructured":"Ritter A, Quartermaine C, Pierre-Charles J, Balasubramanian S, Raeisi-Giglou P, Addison D, Miller E. Cardiotoxicity of anti-cancer radiation therapy: a focus on heart failure. Curr Heart Fail Rep. 2023, 20:44-55. 10.1007\/s11897-023-00587-0","journal-title":"Curr Heart Fail Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon AR","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, et al.. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020, 22:1945-60. 10.1002\/ejhf.1920","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00153","article-title":"Heart dosimetric parameters were associated with cardiac events and overall survival for patients with locally advanced esophageal cancer receiving definitive radiotherapy","volume":"10","author":"Cai G","year":"2020","unstructured":"Cai G, Li C, Yu J, Meng X. Heart dosimetric parameters were associated with cardiac events and overall survival for patients with locally advanced esophageal cancer receiving definitive radiotherapy. Front Oncol. 2020, 10:153. 10.3389\/fonc.2020.00153","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.07.010","article-title":"How to diagnose and manage radiation cardiotoxicity","volume":"2","author":"Ganatra S","year":"2020","unstructured":"Ganatra S, Chatur S, Nohria A. How to diagnose and manage radiation cardiotoxicity. JACC CardioOncol. 2020, 2:655-60. 10.1016\/j.jaccao.2020.07.010","journal-title":"JACC CardioOncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.829553","article-title":"Multimodality advanced cardiovascular and molecular imaging for early detection and monitoring of cancer therapy-associated cardiotoxicity and the role of artificial intelligence and big data","volume":"9","author":"Kwan JM","year":"2022","unstructured":"Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality advanced cardiovascular and molecular imaging for early detection and monitoring of cancer therapy-associated cardiotoxicity and the role of artificial intelligence and big data. Front Cardiovasc Med. 2022, 9:829553. 10.3389\/fcvm.2022.829553","journal-title":"Front Cardiovasc Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.500","article-title":"Cardiac radiation dose, cardiac disease, and mortality in patients with lung\u00a0cancer","volume":"73","author":"Atkins KM","year":"2019","unstructured":"Atkins KM, Rawal B, Chaunzwa TL, et al.. Cardiac radiation dose, cardiac disease, and mortality in patients with lung\u00a0cancer. J Am Coll Cardiol. 2019, 73:2976-87. 10.1016\/j.jacc.2019.03.500","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1234-z","article-title":"Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)","volume":"14","author":"Jacob S","year":"2019","unstructured":"Jacob S, Camilleri J, Derreumaux S, et al.. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol. 2019, 14:29. 10.1186\/s13014-019-1234-z","journal-title":"Radiat Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.03.93","article-title":"Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer","volume":"12","author":"Newman NB","year":"2020","unstructured":"Newman NB, Anderson JL, Sherry AD, Osmundson EC. Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer. J Thorac Dis. 2020, 12:2395-405. 10.21037\/jtd.2020.03.93","journal-title":"J Thorac Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117 J","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, et al.. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020, 22:1504-24. 10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1667\/RR15130.1","article-title":"Cardiac and renal delayed effects of acute radiation exposure: organ differences in vasculopathy, inflammation, senescence and oxidative balance","volume":"191","author":"Unthank JL","year":"2019","unstructured":"Unthank JL, Ortiz M, Trivedi H, et al.. Cardiac and renal delayed effects of acute radiation exposure: organ differences in vasculopathy, inflammation, senescence and oxidative balance. Radiat Res. 2019, 191:383-97. 10.1667\/RR15130.1","journal-title":"Radiat Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/proteomes8040030","article-title":"Radiation response of human cardiac endothelial cells reveals a central role of the cGAS-STING pathway in the development of inflammation","volume":"8","author":"Philipp J","year":"2020","unstructured":"Philipp J, Le Gleut R, Toerne CV, Subedi P, Azimzadeh O, Atkinson MJ, Tapio S. Radiation response of human cardiac endothelial cells reveals a central role of the cGAS-STING pathway in the development of inflammation. Proteomes. 2020, 8:30. 10.3390\/proteomes8040030","journal-title":"Proteomes"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2019.83710","article-title":"Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction","volume":"22","author":"Zhao L","year":"2019","unstructured":"Zhao L. Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. Anatol J Cardiol. 2019, 22:232-9. 10.14744\/AnatolJCardiol.2019.83710","journal-title":"Anatol J Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm","volume":"3","author":"Zafar A","year":"2021","unstructured":"Zafar A, Drobni ZD, Mosarla R, et al.. The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm. JACC CardioOncol. 2021, 3:101-9. 10.1016\/j.jaccao.2020.12.005","journal-title":"JACC CardioOncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions","volume":"14","author":"Chong JH","year":"2019","unstructured":"Chong JH, Ghosh AK. Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions. Interv Cardiol. 2019, 14:89-94. 10.15420\/icr.2019.12","journal-title":"Interv Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2019.04.006","article-title":"Beta-blockers: historical perspective and mechanisms of action","volume":"72","author":"Oliver E","year":"2019","unstructured":"Oliver E, Mayor F Jr, D'Ocon P. Beta-blockers: historical perspective and mechanisms of action. Rev Esp Cardiol (Engl Ed). 2019, 72:853-62. 10.1016\/j.rec.2019.04.006","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.48095\/ccko2022307","article-title":"Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck","volume":"35","author":"Dubinsk\u00fd P","year":"2022","unstructured":"Dubinsk\u00fd P, Jeremic B, \u0160vajdov\u00e1 M, Baril\u00edkov\u00e1 G, Matula P, Nadzonov\u00e1 D, Vojtek V. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck. Klin Onkol. 2022, 35:307-14. 10.48095\/ccko2022307","journal-title":"Klin Onkol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105573","article-title":"Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials","volume":"169","author":"Bao J","year":"2021","unstructured":"Bao J, Kan R, Chen J, Xuan H, Wang C, Li D, Xu T. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials. Pharmacol Res. 2021, 169:105573. 10.1016\/j.phrs.2021.105573","journal-title":"Pharmacol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332487-cardiotoxicity-of-chemoradiotherapy-in-patients-with-esophageal-cancer-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:51:36Z","timestamp":1767617496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332487-cardiotoxicity-of-chemoradiotherapy-in-patients-with-esophageal-cancer-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.100822","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}